Kounis Syndrome (Allergic Angina/Infarction)

1. Executive Overview: What is Kounis Syndrome?

Kounis Syndrome, often referred to as "allergic angina" or "allergic myocardial infarction," is a complex clinical entity defined by the concurrence of acute coronary syndromes (ACS) with conditions associated with mast cell activation, such as allergic, hypersensitivity, anaphylactic, or anaphylactoid reactions.

First described by Dr. Nicholas Kounis in 1991, this syndrome represents a critical intersection between immunology and cardiology. It is characterized by the release of inflammatory mediators—including histamine, neutral proteases (tryptase and chymase), arachidonic acid products, platelet-activating factor, and various cytokines—following an allergic insult. These mediators exert direct deleterious effects on the coronary vasculature, leading to coronary artery spasm, plaque erosion, or rupture, and subsequent myocardial ischemia or infarction.

The ICD-10 code I20.8_2 is utilized to categorize this condition, reflecting its status as a distinct form of angina triggered by allergic mechanisms rather than traditional atherosclerotic progression alone.

2. Pathophysiology, Etiology, and Risk Factors

The Mast Cell Connection

The pathophysiology of Kounis Syndrome is rooted in the activation of cardiac mast cells. When a patient is exposed to an allergen (e.g., medication, venom, food, or environmental trigger), mast cells residing in the coronary artery walls and the heart muscle degranulate.

• Histamine: Causes coronary artery vasoconstriction and increases vascular permeability.
• Tryptase/Chymase: These neutral proteases activate matrix metalloproteinases, which contribute to the degradation of the fibrous cap of atherosclerotic plaques, leading to rupture.
• Leukotrienes: Extremely potent vasoconstrictors that can sustain coronary spasm long after the initial allergic reaction has subsided.

Etiological Triggers

The triggers for Kounis Syndrome are vast and often unpredictable. They are generally classified into three types:

Classification of Kounis Syndrome

Clinicians classify the syndrome into three distinct types:
1. Type I (Coronary Spasm): Occurs in patients with normal coronary arteries. It is the result of endothelial dysfunction or spasm.
2. Type II (Plaque Erosion/Rupture): Occurs in patients with pre-existing quiescent coronary artery disease. The allergic insult triggers plaque rupture, leading to myocardial infarction.
3. Type III (Stent Thrombosis): Specifically involves the thrombosis of a drug-eluting stent (DES), often triggered by hypersensitivity to the stent material (e.g., polymers or metals).

3. Signs, Symptoms, and Clinical Presentation

The clinical presentation of Kounis Syndrome is a "double-edged sword," as symptoms of an allergic reaction often mask the underlying cardiac distress.

Allergic Symptoms:
* Urticaria (hives) or generalized pruritus.
* Angioedema (swelling of lips, face, or throat).
* Bronchospasm or wheezing.
* Hypotension and tachycardia (often attributed solely to anaphylaxis).

Cardiac Symptoms:
* Substernal chest pain (angina pectoris).
* Diaphoresis (excessive sweating).
* Nausea and vomiting.
* Syncope or pre-syncope.
* Dyspnea (shortness of breath).

Clinical Clue: If a patient develops sudden onset chest pain during or immediately following an allergic reaction, clinicians must maintain a high index of suspicion for Kounis Syndrome.

4. Standard Diagnostic Evaluation & Workup

Diagnosing Kounis Syndrome requires a multidisciplinary approach combining immunology and cardiology.

Laboratory Assays

• Serum Tryptase: The gold standard marker for mast cell activation. It should be measured within 1–2 hours of symptom onset.
• Cardiac Biomarkers: Troponin I or T levels are essential to determine if myocardial injury (infarction) has occurred.
• Histamine levels: Though harder to measure due to a short half-life, elevated levels confirm the allergic etiology.

Imaging and Functional Testing

• Electrocardiogram (ECG): May show ST-segment elevation or depression, T-wave inversion, or arrhythmias consistent with ischemia.
• Echocardiography: Useful for assessing wall motion abnormalities, which confirm myocardial ischemia.
• Coronary Angiography: Necessary to distinguish between Type I (normal vessels/spasm) and Type II (atherosclerotic disease) variants.

Diagnostic Criteria (Summary)

A diagnosis is generally made when a patient presents with acute coronary syndrome symptoms concurrent with allergic symptoms, and where the allergic event is clearly temporally related to the cardiac event.

5. Therapeutic Interventions

The management of Kounis Syndrome is delicate because some standard cardiac medications (like beta-blockers) can potentially worsen allergic reactions, while some allergy medications can affect cardiac performance.

Immediate Pharmacotherapy

1. Stabilizing the Allergic Reaction: Corticosteroids (e.g., methylprednisolone) and H1/H2 antihistamines (e.g., diphenhydramine and famotidine) are the first-line defense to dampen the mast cell response.
2. Addressing Coronary Spasm: Calcium channel blockers (e.g., diltiazem or verapamil) are preferred as they act as both coronary vasodilators and mast cell stabilizers.
3. Avoiding Triggers: Immediate discontinuation of the offending agent.

The "Cautionary" List

• Beta-Blockers: Should be avoided in the acute phase of Kounis Syndrome because they can exacerbate coronary vasospasm by leaving alpha-adrenergic receptors unopposed and may worsen anaphylaxis.
• Epinephrine: Used with extreme caution. While necessary for anaphylaxis, it can worsen coronary ischemia and induce arrhythmias. It should be used at the lowest effective dose if hemodynamic collapse is imminent.

Surgical and Long-term Management

• PCI (Percutaneous Coronary Intervention): Required if there is a documented thrombus (Type II or III).
• Desensitization: If the trigger is a necessary medication, patients may undergo a formal desensitization protocol later.
• Lifestyle: Strict avoidance of the identified allergen is the cornerstone of long-term prognosis. Patients should carry an epinephrine auto-injector if the allergy is severe.

6. Frequently Asked Questions (FAQ)

1. Is Kounis Syndrome fatal?
If left untreated, it can lead to myocardial infarction and fatal arrhythmias. However, with prompt recognition and dual management of the allergy and the heart, the prognosis is generally favorable.

2. Can any allergy cause Kounis Syndrome?
Yes, any allergen that triggers systemic mast cell degranulation has the potential to induce the syndrome, though drugs and insect stings are the most common culprits.

3. How is it different from a regular heart attack?
A typical heart attack is caused by plaque buildup or clot formation. Kounis Syndrome is triggered by an allergic inflammatory cascade that leads to spasm or plaque rupture.

4. Why are beta-blockers dangerous for this condition?
Beta-blockers can block the relaxation of the bronchial smooth muscle and may leave alpha-receptors unopposed, which can worsen coronary artery spasms.

5. What is the role of the cardiologist in treatment?
The cardiologist manages the ischemic heart injury while working with an allergist to identify the trigger and prevent recurrence.

6. Do I need to be on long-term medication?
Only if you have underlying coronary artery disease. Otherwise, avoiding the allergen is the primary preventative measure.

7. Is it common?
It is considered an underdiagnosed condition. Because allergic symptoms often overshadow cardiac symptoms, many cases are mislabeled as simple anaphylaxis.

8. Can a food allergy cause this?
Yes, severe allergic reactions to food (e.g., peanuts, shellfish) can lead to systemic anaphylaxis, which can subsequently trigger Kounis Syndrome.

9. How long does the risk of heart attack last after an allergy?
The risk is highest during the acute phase of the allergic reaction, but systemic inflammation can persist for hours, necessitating careful monitoring.

10. What should I do if I suspect I have it?
If you experience chest pain alongside hives, swelling, or difficulty breathing, seek emergency medical care immediately and inform the staff about the potential allergic trigger.

Related Clinical Integration

In the management of Kounis Syndrome, a multidisciplinary approach is essential to address the concurrent allergic reaction and acute coronary event. Initial stabilization requires the judicious administration of Epinephrine / إبينفرين 1mg/10ml, Antihistamines (e.g., Diphenhydramine - for contrast reaction management) / مضادات الهيستامين (مثل ديفينهيدرامين - لإدارة تفاعلات التباين) Standard, and Corticosteroids / الكورتيكوستيرويدات Standard to mitigate mast cell degranulation and systemic inflammation. Once the patient is hemodynamically stabilized, Coronary Angiography / تصوير الشرايين التاجية (فحص بالمنظار أو أخذ عينات) is often indicated to evaluate for coronary vasospasm or plaque rupture, though clinicians must remain vigilant regarding the potential for contrast-induced hypersensitivity. In complex cases where the patient may require intensive care or renal support, specialized equipment such as Hemodialysis Catheter Clamping Forceps / ملقط تثبيت قسطرة غسيل الكلى الدموي may be utilized during the management of secondary complications or comorbid conditions, ensuring a comprehensive and safe clinical workflow.